Diabetes Spectrum Reports a Study Assessing the i-port(R) Injection Port for Administration ...( Device a Viable Alternative to ...),Health

Device a "Viable Alternative" to Standard Injections - 69% of Patients Report i-port(R) is Helpful in the Management of Their Diabetes

AUSTIN, Texas, Sept. 17 /PRNewswire/ -- In a clinical trial comparing the i-port(R) (a small, disposable injection port about the size of a quarter) with standard injections in people with type 1 and type 2 diabetes, participants' differences in glycosylated albumin was not significantly different. The new data appeared in an article published in the current issue (Summer, 2008) of Diabetes Spectrum, a peer-reviewed journal of the American Diabetes Association. Glycosylated albumin is a direct measure of short term glucose in blood protein. Based on these results, the authors conclude that the utility and efficacy of administering multiple doses of insulin through a single i-port(R) device is a viable alternative to standard injections. View the complete abstract and/or purchase the feature article at http://spectrum.diabetesjournals.org/cgi/content/abstract/21/3/197.

"Our study demonstrates that delivering insulin via the i-port(R) provides the same therapeutic benefits as standard injections," said lead investigator Dr. Thomas Blevins of Texas Diabetes and Endocrinology in Austin, Texas. "This is especially significant for people with diabetes who struggle with adherence and need an alternative to the multiple daily skin punctures required by standard injections."

The prospective, randomized, controlled, open-label crossover study enrolled 74 patients with diabetes being treated with daily insulin injections at five trial sites. Participants were randomly assigned to two of three injection treatment regimens including standard injection, injecting through a single i-port(R) device, and injecting through two separate i-port(R) devices with each regimen lasting three weeks. Patients using the single i-port(R)
'/>"/>